Display options
Cite
Wang SL, Dong WB, Dong XL, et al. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget. 2017;8(42):72700-72713doi: 10.18632/oncotarget.20282.
Wang, S. L., Dong, W. B., Dong, X. L., Zhu, W. M., Wang, F. F., Han, F., & Yan, X. (2017). Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget, 8(42), 72700-72713. https://doi.org/10.18632/oncotarget.20282
Wang, Shao-Lian, et al. "Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus." Oncotarget vol. 8,42 (2017): 72700-72713. doi: https://doi.org/10.18632/oncotarget.20282
Wang SL, Dong WB, Dong XL, Zhu WM, Wang FF, Han F, Yan X. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget. 2017 Aug 16;8(42):72700-72713. doi: 10.18632/oncotarget.20282. eCollection 2017 Sep 22. PMID: 29069819; PMCID: PMC5641162.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 16;8(42):72700-72713. doi: 10.18632/oncotarget.20282. eCollection 2017 Sep 22.

Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.

Oncotarget

Shao-Lian Wang, Wen-Bin Dong, Xiao-Lin Dong, Wen-Min Zhu, Fang-Fang Wang, Fang Han, Xin Yan

Affiliations

  1. Department of Endocrinology, Jinan Central Hospital, Jinan 250013, P.R. China.
  2. Pharmaceutical Preparation Section, Jinan Central Hospital, Jinan 250013, P.R. China.

PMID: 29069819 PMCID: PMC5641162 DOI: 10.18632/oncotarget.20282

Abstract

We performed a network meta-analysis to compare the efficacy of 12 single-drug regimens (Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, Sitaglitin, Exenatide, Liraglutide, Acarbose, Benfluorex, and Glipizide) in the treatment of type 2 diabetes mellitus (T2DM). Fifteen relevant randomized controlled trials (RCTs) were included; direct and indirect evidence from these studies was combined, and weighted mean difference (WMD) and surface under the cumulative ranking curves (SUCRAs) were examined to evaluate the monotherapies. Liraglutide was more effective than Glimepiride, Pioglitazone, Sitaglitin, Exenatide, and Glipizide at reducing glycated hemoglobin (HbA1c) levels. In contrast, Acarbose was less effective than Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, and Liraglutide at decreasing HbA1c levels. Reductions in fasting plasma glucose (FPG) levels were similar after all treatments. Rosiglitazone was less effective than Glibenclamide and Repaglinide at reducing total cholesterol (TC) levels. High density lipoprotein (HDL), low density lipoprotein (LDL), and triglyceride levels did not differ after treatment with any of the monotherapies. HbA1c and FPG SUCRA values were highest for Liraglutide, while HbA1c and FPG values were lowest for Acarbose, and TC and LDL values were lowest for Rosiglitazone. These results suggest that Liraglutide may be most effective, and Acarbose least effective, at reducing blood glucose levels, while Glibenclamide, Repaglinide, and Metformin may be most effective, and Rosiglitazone least effective, at reducing lipoidemia, in T2DM patients.

Keywords: effects; network meta-analysis; randomized controlled trials; single-drug regimen; type 2 diabetes mellitus

Conflict of interest statement

CONFLICTS OF INTEREST The author declare no conflicts of interest.

References

  1. Acta Diabetol. 2003 Mar;40(1):20-7 - PubMed
  2. J Clin Epidemiol. 2011 Feb;64(2):163-71 - PubMed
  3. Diabetes Care. 2010 Aug;33(8):1759-65 - PubMed
  4. PLoS One. 2015 Apr 13;10(4):e0123153 - PubMed
  5. Diab Vasc Dis Res. 2012 Jul;9(3):238-40 - PubMed
  6. Diabet Med. 2001 May;18(5):395-401 - PubMed
  7. Pharmacology. 2014;94(3-4):115-22 - PubMed
  8. PLoS One. 2013 Oct 03;8(10):e76654 - PubMed
  9. Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):311-321 - PubMed
  10. Korean J Urol. 2013 May;54(5):289-96 - PubMed
  11. Am J Cardiovasc Drugs. 2007;7(5):319-35 - PubMed
  12. Lancet. 2002 Jun 15;359(9323):2072-7 - PubMed
  13. BMJ Open. 2016 Jul 26;6(7):e010197 - PubMed
  14. Aliment Pharmacol Ther. 2015 Apr;41(7):624-35 - PubMed
  15. Antimicrob Agents Chemother. 1989 Nov;33(11):2004-5 - PubMed
  16. Acta Diabetol. 2009 Mar;46(1):27-33 - PubMed
  17. Metabolism. 2008 Sep;57(9):1248-52 - PubMed
  18. Eur J Clin Pharmacol. 2017 Jan;73(1):1-14 - PubMed
  19. Evid Based Complement Alternat Med. 2013;2013:343594 - PubMed
  20. Am J Public Health. 1992 Sep;82(9):1295 - PubMed
  21. Diabetes. 2012 Mar;61(3):708-15 - PubMed
  22. Mayo Clin Proc. 2014 Jun;89(6):806-16 - PubMed
  23. Expert Opin Drug Discov. 2013 Nov;8(11):1339-63 - PubMed
  24. J Diabetes Res. 2014;2014:294017 - PubMed
  25. Ann Pharmacother. 2013 Oct;47(10):1348-52 - PubMed
  26. J Diabetes Res. 2016;2016:3694957 - PubMed
  27. World J Diabetes. 2016 Sep 15;7(17):354-95 - PubMed
  28. J Clin Periodontol. 2012 Mar;39(3):303-14 - PubMed
  29. Diabetol Metab Syndr. 2016 Feb 27;8:15 - PubMed
  30. Aust Fam Physician. 2016 Jun;45(6):401-6 - PubMed
  31. Diabetes Res Clin Pract. 2004 Feb;63(2):127-34 - PubMed
  32. Diabetologia. 2003 Dec;46(12):1611-7 - PubMed
  33. Am Heart J. 2007 Mar;153(3):445.e1-6 - PubMed
  34. Lancet. 2009 Feb 7;373(9662):473-81 - PubMed
  35. Circulation. 2004 Jul 13;110(2):214-9 - PubMed
  36. Eur J Pharmacol. 2011 May 20;659(1):89-93 - PubMed
  37. Obesity (Silver Spring). 2010 Oct;18(10):2058-60 - PubMed
  38. Diabetes Res Clin Pract. 1999 Mar;43(3):155-66 - PubMed
  39. Nutr Metab Cardiovasc Dis. 2007 Jan;17(1):13-23 - PubMed
  40. BMJ. 2011 Oct 18;343:d5928 - PubMed
  41. PLoS One. 2014 Jul 02;9(7):e100778 - PubMed
  42. Diabetes Care. 2014 Sep;37(9):2451-8 - PubMed
  43. Blood Coagul Fibrinolysis. 2011 Sep;22(6):512-20 - PubMed

Publication Types